Who Really Needs Ozempic Anyway?
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
Who Really Needs Ozempic Anyway?
-
Narrated by:
-
Written by:
This week on Prosthetic Gods, Nir and J discuss the tradeoffs of GLP1 drugs. Their use has reversed the obesity epidemic and has proven to have myriad medical and psychological benefits. But they also come with risks, and are seen as a technofix replacing the need for diets. Are GLP1s another step to the posthuman body, and is that a good or bad thing?
Errata: The first GLP1s were approved by the FDA in 2005, semaglutide/Ozempic in 2017, and oral orforglipron/Foundayo was approved in April 2026. More than two thirds of American adults are overweight or obese by BMI, and 40% are obese.
Show Notes:GLP-1s Are a Lot Weirder Than Anyone Thought | The Ezra Klein Show
Ethical Considerations in the Use of Weight Loss Medications
The Ethics of Ozempic and Wegovy
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
Review of 64 studies finds GLP1s effective for weight loss for almost all groups
Obesity rate declining in US
Hard Fork Podcast
Rest is History Podcast
As always, listeners can contact us at prostheticgods@gmail.com with questions, comments, and suggestions for future topics.
Credits:Hosted by James Hughes and Nir Eisikovits Music & Production by Jake Burley